EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors

Olivera Casar-Borota iD, Pia Burman iD, M Beatriz Lopes iD

Brain Pathology · 2025-01 · 35 (1)

DOI: 10.1111/bpa.13302 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain Pathology, 2024-09. Verfasst von Olivera Casar-Borota und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Pituitary Neoplasms, World Health Organization, Neuroendocrine Tumors. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The vast majority of pituitary neuroendocrine tumors (PitNETs) are benign and slow growing with a low relapse rate over many years after surgical resection. However, about 40% are locally invasive and may not be surgically cured, and about one percentage demonstrate an aggressive clinical behavior. Exceptionally, these aggressive tumors may metastasize outside the sellar region to the central nervous system and/or systemically. The 2017 (4th Edition) WHO Classification of Pituitary Tumors abandoned the terminology “atypical adenoma” for tumors previously considered to have potential for a more aggressive behavior since its prognostic value was not established. The 2022 (5th Edition) WHO Classification of the Pituitary Tumors emphasizes the concept that morphological features distinguish indolent tumors from locally aggressive ones, however, the proposed histological subtypes are not consistent with the real life clinical characteristics of patients with aggressive tumors/carcinomas. So far, no single clinical, radiological or histological parameter can determine the risk of growth or malignant progression. Novel promising molecular prognostic markers, such as mutations in ATRX, TP53, SF3B1, and epigenetic DNA modifications, will need to be verified in larger tumor cohorts. In this review, we provide a critical analysis of the WHO guidelines for prognostic stratification and diagnosis of aggressive and metastatic PitNETs. In addition, we discuss the new WHO recommendations for changing ICD‐O and ICD‐11 codes for PitNET tumor behavior from a neoplasm either “benign” or “unspecified, borderline, or uncertain behavior” to “malignant” neoplasm regardless of the clinical presentation, histopathological subtype, and tumor location. We encourage multidisciplinary initiatives for integrated clinical, histological and molecular classification, which would enable early recognition of these challenging tumors and initiation of more appropriate and aggressive treatments, ultimately improving the outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary NeoplasmsWorld Health OrganizationNeuroendocrine TumorsHumansPrognosis

Stichwörter der Autor:innen

PitNETmetastatic pituitary tumorpituitary adenomapituitary carcinomapituitary neuroendocrine tumor

Autor:innen und Institutionen

  • Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
  • Department of Clinical Pathology, Uppsala University Hospital, Uppsala, Sweden.
  • Department of Endocrinology, Skåne University Hospital, Lund University, Malmö, Sweden.
  • Department of Pathology, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.

ORCID-Profile: Olivera Casar-Borota, Pia Burman, M Beatriz Lopes

Zitieren

APA

Casar-Borota, O., Burman, P., & Lopes, M. B. (2025). The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors. Brain Pathology, 35(1). https://doi.org/10.1111/bpa.13302

Vancouver

Casar-Borota O, Burman P, Lopes MB. The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors. Brain Pathology. 2025;35(1). doi:10.1111/bpa.13302

BibTeX
@article{CasarBorota2025,
  author = {Casar-Borota, Olivera and Burman, Pia and Lopes, M Beatriz},
  title = {The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors},
  journal = {Brain Pathology},
  year = {2025},
  volume = {35},
  number = {1},
  doi = {10.1111/bpa.13302}
}
Kostenlos starten →